Showing papers in "Annals of Oncology in 2023"

TL;DR: The ESMO Clinical Practice Guideline as discussed by the authors provides key recommendations and algorithms for managing oncogene-addicted non-small-cell lung cancer (NSCLC) patients, including diagnosis, staging, risk assessment, treatment and disease monitoring.

TL;DR: In this paper , the authors proposed a systematic collaboration and frequent communication between pathologists and interventionalists to maximize the diagnostic yield of lung cancer samples, e.g. from sites within the thorax.

TL;DR: Horváth-Puhó et al. as discussed by the authors found that the risk of venous thromboembolism in cancer patients is higher than in those without cancer across all age categories.

TL;DR: The OpACIN-neo trial as mentioned in this paper showed that the median recurrence-free survival (RFS) and overall survival (OS) were not reached in either trial, and the estimated 3-year RFS and OS rates were 82% and 92%, respectively.

TL;DR: In this article , the authors used cancer death certification and population data from the World Health Organization and Eurostat databases for 1970-2018, and predicted numbers of deaths and age-standardized rates (ASRs) for 2023 for all cancers combined and the 10 most common cancer sites.

TL;DR: In this article , a refined and validated microenvironment cell population (MCP) counter method was applied to >800 GBM patient tumours (GBM-MCP-counter).

TL;DR: APPLE as mentioned in this paper is a randomized, non-comparative, phase II study in patients with common EGFR-mutant, treatment-naive non-small-cell lung cancer.

TL;DR: In this article , the authors evaluated whether tissue tumor mutational burden (tTMB) and STK11, KEAP1, and KRAS mutations have clinical utility as biomarkers for pembrolizumab monotherapy versus platinum-based chemotherapy in patients with PD-L1-positive (tumor proportion score ≥ 1%) advanced/metastatic non-small-cell lung cancer (NSCLC) without EGFR/ALK alterations in the phase III KEYNOTE-042 trial.

TL;DR: The first interim analysis of the phase III, randomized, double-blind, placebo-controlled, multinational TITAN study demonstrated improved overall survival (OS) and radiographic progression-free survival (rPFS) with apalutamide added to ongoing androgen deprivation therapy (ADT) in patients with metastatic castration-sensitive prostate cancer as mentioned in this paper .

TL;DR: In this paper , the impact of comprehensive molecular profiling of ctDNA in patients with advanced solid tumors was investigated, where the authors used the FoundationOne Liquid CDx Assay to perform a prospective study and found that at least one actionable target was detected in 1059 patients (64%) with a total of 1825 actionable alterations including alteration of the DNA damage repair response pathway (n = 336, 18%), high TMB (>16 mutations/Mb; n = 243, 13%), PIK3CA mutations, ERBB family pathway alterations, PTEN alterations, FGFR alterations and MET activations.

TL;DR: In this paper , the authors conducted an early-phase clinical trial of a cultivated, orally delivered 30-species microbial consortium (Microbial Ecosystem Therapeutic 4, MET4) designed for co-administration with ICIs as an alternative to FMT and assessed safety, tolerability and ecological responses in patients with advanced solid tumors.

TL;DR: In the DESTINY-Breast03 clinical trial, trastuzumab deruxtecan (T-DXd) showed superior progression-free survival and overall survival compared with T-DM1 and manageable safety in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer as discussed by the authors .

TL;DR: Genomic alterations were characterised using next-generation sequencing from a subset of 1276 patients (deep targeted sequencing, n = 1258; whole-exome sequencing in a young-age, case-control subsample,n = 82) to determine genomic drivers that are enriched in young premenopausal women as discussed by the authors .

TL;DR: The European Society for Medical Oncology (ESMO) held a virtual consensus-building process focused on HER2-low breast cancer between 2022 and 2023, which included a multidisciplinary panel of 32 leading experts in the management of breast cancer from 9 different countries as mentioned in this paper .

TL;DR: In this paper , the authors proposed a method to solve the problem of "uniformity" and "uncertainty" in the context of online learning, i.e.,

TL;DR: Kotikonda et al. as discussed by the authors proposed an ESMO awareness call to improve sponsored and monitoring of clinical trials, which is called Streamlining Clinical Research: An ESMO Awareness Call to improve Sponsoring and Monitoring of Clinical Trials.

TL;DR: In this paper , circulating tumor DNA (ctDNA) sequencing was used to analyze plasma samples prospectively collected in the phase III VOYAGER trial to understand how the KIT/PDGFRA mutational landscape contributes to tyrosine kinase inhibitor (TKI) resistance.

TL;DR: Perez-Gracia et al. as mentioned in this paper proposed an ESMO awareness call to improve sponsored and monitoring of clinical trials, which was supported by the American Society of Oncology (ASO).

TL;DR: In this paper , the authors evaluated the performance of enhanced linear-splinter amplification sequencing, a previously described cell-free DNA (cfDNA) methylation-based technology, in the early detection and localization of six types of cancers in the colorectum, esophagus, liver, lung, ovary, and pancreas.

TL;DR: In this article , the authors conducted a randomized controlled trial among patients with cancer aged ≥18 years having average pain score ≥4 on a numerical rating scale of 0-10 to assess the ‘time to achieve stable pain control’ (pain score ≤3 for 3 consecutive days).

TL;DR: Wang et al. as mentioned in this paper evaluated the efficacy and safety of surufatinib in the treatment for intrahepatic cholangiocarcinoma (ICC) patients.

TL;DR: The multicenter, randomized, phase IV, intergroup AGO-B WSG PreCycle trial (NCT03220178) as mentioned in this paper evaluated the impact of CANKADO-based electronic patient-reported outcome (ePRO) assessment on quality of life (QoL) in hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer (MBC) patients receiving palbociclib and an aromatase inhibitor or palbocaliclib + fulvestrant.

TL;DR: Olaparib plus bevacizumab provided clinically meaningful OS improvement for first-line patients with HRD-positive ovarian cancer as mentioned in this paper , despite a high proportion of patients receiving poly(ADP-ribose) polymerase inhibitors after progression, confirming the combination as one of the standards of care in this setting with the potential to enhance cure.

TL;DR: In this article , a machine learning-based model was developed to classify tumors into one of three categories: inflamed, altered, and desert, based on the spatial distribution of CD8+ T cells in two prospective and retrospective NSCLC surgical cohorts.

TL;DR: In this article , the authors analyzed clinicogenomic data from 1817 patients with KRAS-mutant lung adenocarcinoma (LUAD) sequenced at the Dana-Farber Cancer Institute (DFCI) and Memorial Sloan Kettering Cancer Center (MSKCC).

TL;DR: XQ-350 is a nanoveicle of Saposin C, an allosteric activator of sphingolipid metabolism, that lowers systemic S1P and increases C18 ceramide as mentioned in this paper .

TL;DR: In this paper , the authors determined the incidence of EOPC and LOPC in the 7th decade of life and their correlation with epidemiological and clinicopathological features.

TL;DR: The IMPROVE study as discussed by the authors evaluated continuous until progressive disease (PD) or intermittent FOLFIRI plus Panitumumab (FolFIRI/PANI), in patients (pts) with unresectable and previously untreated RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC).